$SILO
Silo Pharma, Inc. Stock $silo

$silo Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024025615 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.03K	$18.03K	$72.10K
YoY Change	-72.0%	0.0%	-0.74%
Cost Of Revenue	$1.460K	$1.460K	$5.838K
YoY Change	0.0%	0.0%	0.0%
Gross Profit	$16.57K	$16.57K	$66.26K
YoY Change	0.0%	0.0%	0.0%
Gross Profit Margin	91.9%	91.9%	91.9%
Selling, General & Admin	$64.36K	$843.3K	$390.1K
YoY Change	-0.93%	-18.82%	71.64%
% of Gross Profit	388.52%	5089.5%	588.66%
Research & Development	$318.2K	$337.0K	$845.1K
YoY Change	56.84%	-46.91%	-34.31%
% of Gross Profit	1921.04%	2033.61%	1275.34%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$896.1K	$1.180M	$3.922M
YoY Change	9.27%	-29.47%	6.17%
Operating Profit	-$879.5K	-$1.164M	-$3.856M
YoY Change	9.46%	-29.77%	6.28%
Interest Expense	$1.870K	$112.2K	$4.869K
YoY Change	12.99%	-1920.62%	121.42%
% of Operating Profit
Other Income/Expense, Net	$77.85K	$0.00	$224.5K
YoY Change	-175.64%	-100.0%	-180.26%
Pretax Income	-$801.7K	-$1.052M	-$3.631M
YoY Change	-11.55%	-36.76%	-7.07%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$801.7K	-$1.121M	-$3.701M
YoY Change	-11.55%	-32.57%	-5.32%
Net Earnings / Revenue	-4447.28%	-6218.41%	-5132.57%
Basic Earnings Per Share	-$0.28
Diluted Earnings Per Share	-$0.28	-$0.38	-$1.20
COMMON SHARES
Basic Shares Outstanding	2.844M shares	3.109M shares	3.080M shares
Diluted Shares Outstanding	2.867M shares		3.080M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.744M	$7.665M	$7.665M
YoY Change	-36.87%	-32.58%	-32.58%
Cash & Equivalents	$2.668M	$3.524M	$3.524M
Short-Term Investments	$4.076M	$4.141M	$4.141M
Other Short-Term Assets	$133.8K	$15.97K	$15.97K
YoY Change	-34.54%	-88.25%	-88.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.878M	$7.681M	$7.681M
YoY Change	-37.21%	-33.62%	-33.62%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$63.52K	$64.98K	$64.98K
YoY Change	-8.42%	-8.25%	-8.25%
Total Long-Term Assets	$63.52K	$64.98K	$64.98K
YoY Change	-8.42%	-8.24%	-8.25%
TOTAL ASSETS
Total Short-Term Assets	$6.878M	$7.681M	$7.681M
Total Long-Term Assets	$63.52K	$64.98K	$64.98K
Total Assets	$6.941M	$7.746M	$7.746M
YoY Change	-37.03%	-33.47%	-33.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$801.6K	$703.5K	$703.5K
YoY Change	21.4%	93.15%	93.15%
Accrued Expenses
YoY Change
Deferred Revenue		$72.10K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$873.7K	$775.6K	$775.6K
YoY Change	19.29%	77.76%	77.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$775.7K	$793.7K	$793.7K
YoY Change	-8.51%	-8.33%	-8.33%
Total Long-Term Liabilities	$775.7K	$793.7K	$793.7K
YoY Change	-8.51%	-8.33%	-8.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$873.7K	$775.6K	$775.6K
Total Long-Term Liabilities	$775.7K	$793.7K	$793.7K
Total Liabilities	$1.649M	$1.569M	$1.569M
YoY Change	4.38%	20.52%	20.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.67M	-$10.87M
YoY Change	44.52%	51.61%
Common Stock	$316.00	$316.00
YoY Change	0.0%	0.0%
Preferred Stock		$17.53M
YoY Change		0.08%
Treasury Stock (at cost)	$586.6K	$471.1K
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.292M	$6.177M	$6.177M
YoY Change
Total Liabilities & Shareholders Equity	$6.941M	$7.746M	$7.746M
YoY Change	-37.03%	-33.47%	-33.47%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$801.7K	-$1.121M	-$3.701M
YoY Change	-11.55%	-32.57%	-5.32%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$838.2K	-$914.5K	-$3.224M
YoY Change	21.0%	3.22%	-7.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$97.60K	$4.433M	-$4.147M
YoY Change	-101.62%		-4882.74%
Cash From Investing Activities	$97.60K	$4.433M	-$4.147M
YoY Change	-101.62%		-4882.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$115.5K	-191.1K	-$471.1K
YoY Change			-109.54%
NET CHANGE
Cash From Operating Activities	-$838.2K	-914.5K	-$3.224M
Cash From Investing Activities	$97.60K	4.433M	-$4.147M
Cash From Financing Activities	-$115.5K	-191.1K	-$471.1K
Net Change In Cash	-$856.0K	3.327M	-$7.843M
YoY Change	-87.23%	-475.54%	-612.59%
FREE CASH FLOW
Cash From Operating Activities	-$838.2K	-$914.5K	-$3.224M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.71
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3079874	shares
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41512
CY2023	dei	Entity Registrant Name EntityRegistrantName	SILO PHARMA, INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3046338
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	677 N. Washington Boulevard
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Sarasota
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34236
CY2023	dei	City Area Code CityAreaCode	(718)
CY2023	dei	Local Phone Number LocalPhoneNumber	400-9031
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	SILO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5962382	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2843634	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	106
CY2023	dei	Auditor Name AuditorName	SALBERG & COMPANY, P.A.
CY2023	dei	Auditor Location AuditorLocation	Boca Raton, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3524308	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11367034	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	4140880	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3118	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15970	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135894	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9600	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6010	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	66010	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7681158	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11572056	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	64983	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	70821	usd
CY2023Q4	us-gaap	Assets Assets	7746141	usd
CY2022Q4	us-gaap	Assets Assets	11642877	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	703488	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	364216	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72102	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	775590	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	436318	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	793680	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	865782	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	793680	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	865782	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1569270	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1302100	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3159096	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3158797	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2906241	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3158797	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	316	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	316	usd
CY2023Q4	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	17525714	usd
CY2022Q4	us-gaap	Additional Paid In Capital Preferred Stock AdditionalPaidInCapitalPreferredStock	17511589	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	252855	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Preferred Value TreasuryStockPreferredValue	471121	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6227	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10871811	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7171128	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6176871	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7746141	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11642877	usd
CY2023	us-gaap	Revenues Revenues	72102	usd
CY2022	us-gaap	Revenues Revenues	72102	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	5838	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5838	usd
CY2023	us-gaap	Gross Profit GrossProfit	66264	usd
CY2022	us-gaap	Gross Profit GrossProfit	66264	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	871625	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	577651	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	1726061	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1496687	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	845092	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1286434	usd
CY2023	us-gaap	General Insurance Expense GeneralInsuranceExpense	89007	usd
CY2022	us-gaap	General Insurance Expense GeneralInsuranceExpense	125889	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	390071	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	227259	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3921856	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3693920	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3855592	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3627656	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	398530	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	72637	usd
CY2022	us-gaap	Other Income OtherIncome	85733	usd
CY2023	us-gaap	Interest Expense InterestExpense	4869	usd
CY2022	us-gaap	Interest Expense InterestExpense	2199	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-104700	usd
CY2023	silo	Penalty From Early Termination Of Cd PenaltyFromEarlyTerminationOfCD	166034	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3118	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-331203	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	224509	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-279732	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3631083	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3907388	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3631083	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3907388	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-69600	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1163	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-69600	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1163	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6227	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3706910	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3908551	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.18
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.71
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3079874	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2284240	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9062266	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4940948	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	111014	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	135100	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10340777	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14125	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	471121	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6227	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700683	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6176871	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700683	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3908551	usd
CY2023	silo	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	69600	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-20000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	14125	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	156047	usd
CY2023	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense	90067	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-104700	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3118	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-331203	usd
CY2022	silo	Equity Shares Earned For Services EquitySharesEarnedForServices	-85733	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-35695	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-55335	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	3590	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	4800	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	339272	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-53721	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-72102	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-72102	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3224498	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3497622	usd
CY2023	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	4147107	usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-66707	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	20000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4147107	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	86707	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4940948	usd
CY2023	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	471121	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-471121	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4940948	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7842726	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1530033	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11367034	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9837001	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3524308	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11367034	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4869	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2199	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	25159	usd
CY2023	silo	Change In Accumulated Other Comprehensive Loss And Shortterm Investments ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments	6227	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	135100	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">N<b>OTE 1 – <span style="text-decoration:underline">ORGANIZATION AND BUSINESS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Silo Pharma, Inc. (the “Company”) was incorporated in the State of New York on July 13, 2010, under the name Gold Swap, Inc. On January 24, 2013, the Company changed its state of incorporation from New York to Delaware. On December 19, 2023, the Company changed its state of incorporation from the State of Delaware to the State of Nevada.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The Company seeks to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, post-traumatic stress disorder (“PTSD”), Alzheimer’s, Parkinson’s, and other rare neurological disorders. The Company’s mission is to identify assets to license and fund the research which the Company believes will be transformative to the well-being of patients and the health care industry. The Company was previously engaged in the development of a streetwear apparel brand, NFID (see below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2019, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Point Capital, Inc. to Uppercut Brands, Inc. Thereafter, on September 24, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to change its name from Uppercut Brands, Inc. to Silo Pharma, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2020, the Company incorporated a new wholly-owned subsidiary, Silo Pharma Inc., in the State of Florida. The Company has also secured the domain name www.silopharma.com. The Company had been exploring opportunities to expand the Company’s business by seeking to acquire and/or develop intellectual property or technology rights from leading universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. In July 2020, through the Company’s newly formed subsidiary, the Company entered into a commercial evaluation license and option agreement with University of Maryland, Baltimore (“UMB”) (see Note 8) pursuant to which, among other things, UMB granted the Company an exclusive, option to negotiate and obtain an exclusive, sublicensable, royalty-bearing license to certain technology. The option was extended and exercised on January 13, 2021. On February 12, 2021, the Company entered into a Master License Agreement with UMB (see Note 8). The Company plans to actively pursue the acquisition and/or development of intellectual property or technology rights to treat rare diseases, and to ultimately expand the Company’s business to focus on this new line of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2021, the Company entered into and closed on an Asset Purchase Agreement (the “Asset Purchase Agreement) with NFID, LLC, a Florida limited liability company (the “Buyer”), whereby the Buyer purchased from the Company certain assets, properties, and rights in connection with the Company’s NFID trademark name, logos, domain, and apparel clothing and accessories for a purchase price of $60,000 in the form of a promissory note amounting to $60,000. The promissory note bore 8% interest per annum and matured on October 1, 2023. On November 8, 2023 and effective on October 1, 2023, the Company and the Buyer entered into a First Amendment Promissory Note which increased the interest rate to 9% per annum and extended the maturity date to December 30, 2023 for no consideration. Accordingly, the results of operations of this component, for all periods presented, are separately reported as “discontinued operations” on the accompanying consolidated statements of operations and comprehensive loss (see Note 4). On December 30, 2023, the buyer defaulted on the promissory note (See Note 4).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 14, 2022, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split (the “Reverse Stock Split”) with respect to the outstanding shares of the Company’s common stock. The Certificate of Amendment became effective on September 14, 2022. The Reverse Stock Split was previously approved by the sole director and the majority of stockholders of the Company. The Reverse Stock Split was deemed effective at the open of business on September 15, 2022. All share and per share data in the consolidated financial statements have been retroactively adjusted to reflect the effect of the reverse stock split.</p>
CY2021Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	60000	usd
CY2021Q3	us-gaap	Proceeds From Sale Of Notes Receivable ProceedsFromSaleOfNotesReceivable	60000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3700683	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3224498	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10871811	usd
CY2023Q4	silo	Working Capital WorkingCapital	6905568	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from estimates. Significant estimates during the years ended December 31, 2023 and 2022 include the collectability of notes receivable, the percentage of completion of research and development projects, valuation of equity investments, valuation allowances for deferred tax assets, the fair value of warrants issued with debt, and the fair value of shares and stock options issued for services.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	silo	Cash Spic Insured Amount CashSPICInsuredAmount	250000	usd
CY2023	silo	Penalty From Early Termination Of Cd PenaltyFromEarlyTerminationOfCD	166034	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6227	usd
CY2023	silo	Bad Debt Expense BadDebtExpense	69600	usd
CY2023Q4	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	60000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9600	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15970	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135894	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	64983	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	70821	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	845092	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1286434	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	433429	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	433429	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.99
CY2021Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	60000	usd
CY2023	silo	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	69600	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9600	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6010	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	66010	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1079	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-1079	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	69600	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	84	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-69600	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-1163	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	60000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9600	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6010	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	69600	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	66010	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	69600	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	66010	usd
CY2023	silo	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	69600	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9600	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6010	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	66010	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	105000000	shares
CY2023Q4	silo	Preferred Stock Share Designated PreferredStockShareDesignated	4280	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	227	shares
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	150000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	57500	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.25
CY2022Q3	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	20000	shares
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	135100	usd
CY2022Q3	silo	Restricted Common Share Price RestrictedCommonSharePrice	6.755
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1000000	usd
CY2024Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	1000000	usd
CY2023	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	252855	shares
CY2023Q4	silo	Common Stock Purchase Cost CommonStockPurchaseCost	471121	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan	16000	shares
CY2022Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	6000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	5000	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	5000	shares
CY2023Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	14125	usd
CY2022Q4	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	111014	usd
CY2023	silo	License Agreement Expire LicenseAgreementExpire	P15Y
CY2023	silo	Sublicense Income Receivable Percentage SublicenseIncomeReceivablePercentage	0.25	pure
CY2023	silo	Sales Of Licensed Products Percentage SalesOfLicensedProductsPercentage	0.05	pure
CY2023	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	50000000	usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable	81474	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	60570	usd
CY2023	silo	Research Project Estimate Percentage ResearchProjectEstimatePercentage	0.90	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	725244	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	725244	usd
CY2023	silo	Joint Venture Interest Rate JointVentureInterestRate	0.60	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-777143	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-820796	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-240544	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-254056	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	29510	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	133994	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	988177	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	940858	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2538565	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1550388	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2538565	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1550388	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2538565	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1550388	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9231000	usd
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9231000	usd
CY2023Q4	srt	Financing Receivable Before Allowance For Credit Loss To Total Percent FinancingReceivableBeforeAllowanceForCreditLossToTotalPercent	1	pure
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	988177	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023Q4	silo	Preferred Stock Designated PreferredStockDesignated		shares
CY2022Q4	silo	Preferred Stock Designated PreferredStockDesignated		shares
CY2022Q4	us-gaap	Treasury Stock Preferred Value TreasuryStockPreferredValue		usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023	us-gaap	Other Income OtherIncome		usd
CY2022	silo	Penalty From Early Termination Of Cd PenaltyFromEarlyTerminationOfCD		usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.18
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2284240	shares
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	silo	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations		usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022	silo	Amortization Of Prepaid Stockbased Expense AmortizationOfPrepaidStockbasedExpense		usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023	silo	Equity Shares Earned For Services EquitySharesEarnedForServices		usd
CY2023	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities		usd
CY2022	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities		usd
CY2023	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	silo	Change In Accumulated Other Comprehensive Loss And Shortterm Investments ChangeInAccumulatedOtherComprehensiveLossAndShorttermInvestments		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue		usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue		usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001514183

Files In Submission

Name	View Source	Status
0001213900-24-025615-index-headers.html	Edgar Link	pending
0001213900-24-025615-index.html	Edgar Link	pending
0001213900-24-025615.txt	Edgar Link	pending
0001213900-24-025615-xbrl.zip	Edgar Link	pending
ea0201957-10k_silopharma.htm	Edgar Link	pending
ea020195701ex21-1_silophar.htm	Edgar Link	pending
ea020195701ex23-1_silophar.htm	Edgar Link	pending
ea020195701ex31-1_silophar.htm	Edgar Link	pending
ea020195701ex31-2_silophar.htm	Edgar Link	pending
ea020195701ex32-1_silophar.htm	Edgar Link	pending
ea020195701ex4-1_silophar.htm	Edgar Link	pending
ea020195701ex97-1_silophar.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0201957-10k_silopharma_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
silo-20231231.xsd	Edgar Link	pending
silo-20231231_def.xml	Edgar Link	unprocessable
silo-20231231_lab.xml	Edgar Link	unprocessable
silo-20231231_pre.xml	Edgar Link	unprocessable
silo-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SILO
Silo Pharma, Inc. Stock $silo

2024 Q1 Form 10-K Financial Statement

#000121390024025615 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO Silo Pharma, Inc. Stock $silo

2024 Q1 Form 10-K Financial Statement

#000121390024025615 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SILO
Silo Pharma, Inc. Stock $silo